Dr. Reddy’s Laboratories announced its Q3 FY26 results, showcasing double-digit growth in its base business. Despite product-specific headwinds, the company maintained overall steady profitability. Key highlights include revenue of ₹8,727 Cr, 4.4% year-over-year growth, and an EBITDA margin of 23.5%. The company continues to progress on strategic priorities with new collaborations and product launches.
Financial Performance
Dr. Reddy’s Laboratories reported revenue of ₹8,727 Cr for Q3 FY26, representing a 4.4% year-over-year increase. EBITDA stood at ₹2,049 Cr, with an EBITDA margin of 23.5%. The Profit Before Tax (PBT) reached ₹1,543 Cr, and Profit After Tax (PAT) was ₹1,210 Cr.
Segmental Performance
Global Generics contributed ₹7,911 Cr to the total revenue, showing a 7% year-over-year growth. North America revenues were ₹2,964 Cr. Europe generated revenues of ₹1,448 Cr, up 20% year-over-year, and India’s revenue stood at ₹1,603 Cr, a 19% increase year-over-year. Emerging Markets saw revenues of ₹1,896 Cr.
Key Business Highlights
Dr. Reddy’s entered into a strategic collaboration with Immutep for the commercialization of Eftilagimod Alfa. They also launched Hevaxin®, a novel vaccine for Hepatitis-E in India. The company received marketing authorization for Semaglutide injection in India. Furthermore, the company received EC approval for denosumab biosimilar in Europe and the UK, and launched the product in Germany in December 2025.
ESG and Other Updates
Dr. Reddy’s announced science-based net-zero climate targets, aiming to achieve this by FY2045. The company also maintained a leadership position in the 2025 CDP Water Security & Climate Change assessment. USFDA conducted a GMP inspection at CTO-SEZ API facility and issued Form 483 with zero observations.
Source: BSE
